Avrupa Birliği - Danca - EMA (European Medicines Agency)

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. voksne patienter, der lider af akut koronar syndrom:non-st-segment elevation akut koronar syndrom (ustabil angina pectoris eller non-q-tak myokardieinfarkt), herunder patienter, der gennemgår en stent placering efter perkutan koronar intervention, i kombination med acetylsalicylsyre (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. forebyggelse af atherothrombotic og tromboemboliske hændelser i atrial fibrillationin voksne patienter med atrieflimren, der har mindst en risikofaktor for vaskulære hændelser, er ikke egnede til behandling med vitamin k-antagonister (vka), og som har en lav risiko for blødning, clopidogrel er indiceret i kombination med asa til forebyggelse af atherothrombotic og tromboemboliske hændelser, herunder slagtilfælde.

Avrupa Birliği - Danca - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrelhydrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotiske midler - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. forebyggelse af atherothrombotic og tromboemboliske hændelser i atrial fibrillationin voksne patienter med atrieflimren, der har mindst en risikofaktor for vaskulære hændelser, er ikke egnede til behandling med vitamin-k-antagonister, og som har en lav risiko for blødning, clopidogrel er indiceret i kombination med asa til forebyggelse af atherothrombotic og tromboemboliske hændelser, herunder slagtilfælde.

Danimarka - Danca - SEGES Landbrug & Fødevarer

manglende oplysninger - uspecificeret - flydende middel - 0 g/l uspecificeret

Danimarka - Danca - Lægemiddelstyrelsen (Danish Medicines Agency)

padma europe gmbh - aegle marmelos frugt, pulver, gul potentil, islandsk mos, kaempferia galanga rhizoma, kryddernellike, morgenfrue blomst, myrobalan frugt, paternostertræ, frugt - tabletter

Danimarka - Danca - Lægemiddelstyrelsen (Danish Medicines Agency)

monrol europe s.r.l. - natriumiodid (131-i) - kapsler, hårde - 37-7400 mb

Danimarka - Danca - SEGES Landbrug & Fødevarer

cheminova a/s - dimethoat, gamma-cyhalothrin - flydende middel - 400 g/l dimethoat; 4 g/l gamma-cyhalothrin

Danimarka - Danca - SEGES Landbrug & Fødevarer

cheminova a/s - dimethoat, gamma-cyhalothrin - flydende middel - 400 g/l dimethoat; 6,4 g/l gamma-cyhalothrin

Danimarka - Danca - SEGES Landbrug & Fødevarer

bayer a/s - foramsulfuron, iodosulfuron-methyl-na, iodosulfuron, isoxadifen-ethyl, isoxadifen - od-formulering - 30 g/l foramsulfuron; 1 g/l iodosulfuron-methyl-na; (~ 0,932 g/l iodosulfuron; 30 g/l isoxadifen-ethyl; (~ 27,2 g/l isoxadifen

Danimarka - Danca - SEGES Landbrug & Fødevarer

bayer a/s - thiacloprid - od-formulering - 240 g/l thiacloprid

Danimarka - Danca - Lægemiddelstyrelsen (Danish Medicines Agency)

cis bio international oris ind. - natriummolybdat (99m-mo) - radionuklidgenerator